2021
DOI: 10.1016/j.sapharm.2020.11.016
|View full text |Cite
|
Sign up to set email alerts
|

Deprescribing in older adults during COVID-19 pandemic; Opportunity or risk?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
3

Relationship

2
1

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 9 publications
(9 reference statements)
0
2
0
Order By: Relevance
“…The specific treatments should also be evaluated in the light of the guidelines, which are continuously updated. Due to the fragile nature of the patients, many other aspects should be considered in the evaluation of future studies, such as hospitalization, polypharmacy, co-morbidity, and coexisting chronic conditions, that should be assessed together with specific symptoms of COVID-19 [40][41][42][43].…”
Section: Discussionmentioning
confidence: 99%
“…The specific treatments should also be evaluated in the light of the guidelines, which are continuously updated. Due to the fragile nature of the patients, many other aspects should be considered in the evaluation of future studies, such as hospitalization, polypharmacy, co-morbidity, and coexisting chronic conditions, that should be assessed together with specific symptoms of COVID-19 [40][41][42][43].…”
Section: Discussionmentioning
confidence: 99%
“…This requires great attention from physicians; in fact, polypharmacy is associated with several adverse outcomes, including hospitalization, length of hospital stay and mortality. In a previous study, we described that polypharmacy (5–9 drugs) and excessive polypharmacy (≥10 drugs) are factors associated with polypharmacy status, including not only co-morbidity but also specific symptoms and age [ 15 ].…”
Section: Introductionmentioning
confidence: 99%